At a glance
- Originator Astellas Pharma
- Class
- Mechanism of Action Lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Transplant rejection
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Transplant-rejection in Japan
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
- 18 Mar 2003 Preclinical trials in Transplant rejection in Japan (unspecified route)